NTRA News and Press, Natera Inc. From 05/09/19

SAN CARLOS, Calif. , May 9, 2019 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the first quarter ended March 31, 2019 and provided an update on rec...

SAN CARLOS, Calif. , May 9, 2019 /PRNewswire/ -- A new clinical study shows that Natera's Signatera™ test identified colorectal cancer recurrence up to 16.5 months earlier than radiologic imaging by detecting traces of tumor DNA in the blood after surgery. The test also identifie...

SAN CARLOS, Calif. , May 7, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA) today announced the publication of a clinical validation study demonstrating that its Signatera™ molecular residual disease (MRD) test was highly prognostic of recurrence in patients with bladder ...

SAN CARLOS, Calif. , May 6, 2019 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA) today announced that the U.S. Food and Drug Administration (FDA) has granted "Breakthrough Device" designation for its Signatera™ test for use in the post-surgical detection and quantification of ...

SAN CARLOS, Calif. , May 2, 2019 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its first quarter ended March 31, 2019 , after the mar...

Quick Take CareDx ( CDNA ) announced it has agreed to acquire OTTR Complete Transplant Management for about $16 million. OTTR has developed organ transplant patient tracking software. CDNA gains a reasonably-priced and well-integrated system as it seeks to capitalize on a growing trans...

Natera (NASDAQ: NTRA ) has  priced its public offering of 5,263,158 common shares at $19.00 per share. More news on: Natera, Inc., Healthcare stocks news, Read more ...

SAN CARLOS, Calif. , April 17, 2019 /PRNewswire/ -- Natera, Inc . (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 5,263,158 shares of its common stock at a price to the public of $19.00 per share. Clos...

SAN CARLOS, Calif. , April 16, 2019 /PRNewswire/ --  Natera, Inc . (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $100,000,000 of shares of its common stock. In addition, Natera expects to grant t...

SAN CARLOS, Calif. , April 16, 2019 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), Cancer Research UK , Imperial College London  and the University of Leicester , today announced the publication of results of a clinical study demonstrating that the Signatera&#x...